Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha inhibitors remain the primary treatment for PsA after conventional DMARD failure; however, biologics such as IL-17 inhibitors (Novartis’s Cosentyx, Eli Lilly’s Taltz, UCB’s Bimzelx) and IL-23 inhibitors (Johnson & Johnson Innovative Medicine’s Tremfya, AbbVie’s Skyrizi), and targeted oral therapies such as PDE4 inhibitors and JAK inhibitors (Amgen’s Otezla, Pfizer’s Xeljanz, AbbVie’s Rinvoq) are increasingly challenging the dominance of TNF-alpha inhibitors. Moreover, many patients do not respond adequately to these agents, necessitating alternative treatment strategies. There is a continuous need for effective treatments to address the complexities of PsA, including preventing joint damage. Recognizing these gaps in PsA treatment and focusing on product differentiation may be crucial to the success of a therapy in this space. This report outlines key unmet needs in the treatment of PsA and offers tools for strategic decision-making to compete successfully.
QUESTIONS ANSWERED
- How do current therapies perform on key treatment drivers and goals for PsA?
- When considering AbbVie’s Humira / adalimumab biosimilars, Cosentyx, Bimzelx, Tremfya, Skyrizi, Otezla, and Rinvoq, which drug attributes are key influencers, which have limited impact, and which are the hidden opportunities in PsA?
- What are the prevailing areas of unmet need and opportunity in the PsA market?
- What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new PsA drug?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 63 U.S. and 30 European rheumatologists and dermatologists fielded in December 2025
Key companies: AbbVie, Amgen, UCB, Novartis, Eli Lilly, Johnson & Johnson Innovative Medicine, BMS, Pfizer
Key drugs: Humira, Cosentyx, Bimzelx, Tremfya, Skyrizi, Rinvoq, Otezla
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
